MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma.

Liu, Tao; Gu, Lubing; Wu, Zhongzhi; Albadari, Najah; Li, Wei; Zhou, Muxiang

Liu, Tao; Gu, Lubing; Wu, Zhongzhi; Albadari, Najah; Li, Wei; Zhou, Muxiang.

Afiliação

Liu T; Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, United States.
Gu L; Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, United States.
Wu Z; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Albadari N; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Li W; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Zhou M; Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, United States.

Front Oncol ; 12: 1058726, 2022.

Article em En | MEDLINE | ID: mdl-36505784

Palavras-chave

MDM2; MYCN; cancer; neuroblastoma; small-molecule inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google